CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 129 enrolled
Drug / intervention
hydrochloride hydromorphone + flurbiprofen axetil +1 moredrug
Likely dose
hydrochloride hydromorphone + flurbiprofen axetil 2 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07315022
NCT07315022Phase 4Completed

Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma: a Multicenter Retrospective Cohort Study

First Affiliated Hospital, Sun Yat-Sen University·interventional·Posted Jan 2, 2026·Updated Jan 2, 2026

In Brief

A Phase 4 clinical trial evaluating hydrochloride hydromorphone + flurbiprofen axetil and conventional analgesia for Enhanced Recovery After Surgery and 3 related conditions. Completed, enrolled 129 participants across 1 site.

Detailed Summary

To evaluate the effectiveness of the combination of hydrochloride hydromorphone and flurbiprofen ester for post-TACE intravenous patient-controlled intravenous analgesia (PCIA).

Study Details

Timeline

Phase 4CompletedFinished
20252026
First PostedJan 2, 2026
Enrollment StartAug 1, 2024
Primary CompletionAug 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6 months ago

Interventions

hydrochloride hydromorphone + flurbiprofen axetildrug

Group A received hydromorphone hydrochloride combined with flurbiprofen axetil via PCIA. The pump was initiated 15 min before surgery, with settings of background infusion 2 ml/h, bolus dose 2 ml, and lockout interval 15 min.

conventional analgesiadrug

When the NRS score was ≥4, flurbiprofen axetil 50 mg was administered intravenously, with intramuscular tramadol 100 mg added if analgesia was inadequate.